FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3216802214> ?p ?o ?g. }

• W3216802214 endingPage "925" @default.
• W3216802214 startingPage "918" @default.
• W3216802214 abstract "Eczematous drug eruption (EDE) is a spongiotic skin reaction in response to systemic medications. To date, EDE has been described in patients treated with anti-interleukin (IL)-17A monoclonal antibodies with a prevalence of 2.2%-12.1%.To describe the clinical and histological features and the skin cytokine milieu in patients with EDE induced by anti-IL-17A biologics.This was a prospective study, enrolling patients with psoriasis who developed EDE during treatment with two anti-IL-17 biologics, ixekizumab and secukinumab, from June 2019 to April 2021. Skin biopsies were taken from all patients: a 5-mm lesional biopsy (LB) and a 3-mm nonlesional biopsy (NLB). The LB sample was split into two parts, one for histological examination and the other for cytokine profile evaluation.During the study period, treatment with an anti-IL-17A drug was given to 289 patients of whom 8 (2.8%) developed EDE during the treatment. Histopathological evaluation suggested a diagnosis of spongiotic dermatitis in all eight patients. Cytokine gene expression showed a predominance of T helper (Th)2/Th22 cytokines in EDE lesions with a large increase in IL-4, IL-22 and S100A7 levels in both LB and NLB samples compared with healthy skin. IL-4, IL-22 and S100A7 were significantly higher in LB compared with NLB samples. IL-26 levels were also significantly increased in both LB and NLB compared with healthy skin, whereas low levels of IL-23A were found in both LB and NLB.Eczematous drug eruption skin lesions have mainly Th2/Th22 features, with IL-22 playing a major role in their pathogenesis. EDE seems to be the result of an imbalance towards a Th2/Th22 response, secondary to the blockade of IL-17A activity." @default.
• W3216802214 created "2021-12-06" @default.
• W3216802214 creator A5009455869 @default.
• W3216802214 creator A5014998672 @default.
• W3216802214 creator A5015814702 @default.
• W3216802214 creator A5017757167 @default.
• W3216802214 creator A5025725407 @default.
• W3216802214 creator A5026402548 @default.
• W3216802214 creator A5026649188 @default.
• W3216802214 creator A5029451785 @default.
• W3216802214 creator A5052644127 @default.
• W3216802214 creator A5067678368 @default.
• W3216802214 creator A5079704027 @default.
• W3216802214 date "2022-02-09" @default.
• W3216802214 modified "2023-10-10" @default.
• W3216802214 title "Eczematous drug eruption in patients with psoriasis under anti‐interleukin‐17A: does interleukin‐22 play a key role?" @default.
• W3216802214 cites W1603821607 @default.
• W3216802214 cites W1634158134 @default.
• W3216802214 cites W1644373322 @default.
• W3216802214 cites W1997567742 @default.
• W3216802214 cites W2012077729 @default.
• W3216802214 cites W2017960980 @default.
• W3216802214 cites W2049942972 @default.
• W3216802214 cites W2070483777 @default.
• W3216802214 cites W2070840302 @default.
• W3216802214 cites W2164098277 @default.
• W3216802214 cites W2289486122 @default.
• W3216802214 cites W2530872160 @default.
• W3216802214 cites W2548054746 @default.
• W3216802214 cites W2769637877 @default.
• W3216802214 cites W2890967377 @default.
• W3216802214 cites W2912780583 @default.
• W3216802214 cites W3006129194 @default.
• W3216802214 cites W3088944243 @default.
• W3216802214 cites W3108892713 @default.
• W3216802214 cites W3113122288 @default.
• W3216802214 cites W3132303497 @default.
• W3216802214 cites W3204648622 @default.
• W3216802214 doi "https://doi.org/10.1111/ced.15052" @default.
• W3216802214 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34862807" @default.
• W3216802214 hasPublicationYear "2022" @default.
• W3216802214 type Work @default.
• W3216802214 sameAs 3216802214 @default.
• W3216802214 citedByCount "10" @default.
• W3216802214 countsByYear W32168022142022 @default.
• W3216802214 countsByYear W32168022142023 @default.
• W3216802214 crossrefType "journal-article" @default.
• W3216802214 hasAuthorship W3216802214A5009455869 @default.
• W3216802214 hasAuthorship W3216802214A5014998672 @default.
• W3216802214 hasAuthorship W3216802214A5015814702 @default.
• W3216802214 hasAuthorship W3216802214A5017757167 @default.
• W3216802214 hasAuthorship W3216802214A5025725407 @default.
• W3216802214 hasAuthorship W3216802214A5026402548 @default.
• W3216802214 hasAuthorship W3216802214A5026649188 @default.
• W3216802214 hasAuthorship W3216802214A5029451785 @default.
• W3216802214 hasAuthorship W3216802214A5052644127 @default.
• W3216802214 hasAuthorship W3216802214A5067678368 @default.
• W3216802214 hasAuthorship W3216802214A5079704027 @default.
• W3216802214 hasConcept C126322002 @default.
• W3216802214 hasConcept C16005928 @default.
• W3216802214 hasConcept C2775934546 @default.
• W3216802214 hasConcept C2776260265 @default.
• W3216802214 hasConcept C2778690821 @default.
• W3216802214 hasConcept C2779515644 @default.
• W3216802214 hasConcept C2779745271 @default.
• W3216802214 hasConcept C2779786854 @default.
• W3216802214 hasConcept C2780035454 @default.
• W3216802214 hasConcept C2780439664 @default.
• W3216802214 hasConcept C2780564577 @default.
• W3216802214 hasConcept C47348012 @default.
• W3216802214 hasConcept C50345908 @default.
• W3216802214 hasConcept C71924100 @default.
• W3216802214 hasConcept C74172505 @default.
• W3216802214 hasConcept C98274493 @default.
• W3216802214 hasConceptScore W3216802214C126322002 @default.
• W3216802214 hasConceptScore W3216802214C16005928 @default.
• W3216802214 hasConceptScore W3216802214C2775934546 @default.
• W3216802214 hasConceptScore W3216802214C2776260265 @default.
• W3216802214 hasConceptScore W3216802214C2778690821 @default.
• W3216802214 hasConceptScore W3216802214C2779515644 @default.
• W3216802214 hasConceptScore W3216802214C2779745271 @default.
• W3216802214 hasConceptScore W3216802214C2779786854 @default.
• W3216802214 hasConceptScore W3216802214C2780035454 @default.
• W3216802214 hasConceptScore W3216802214C2780439664 @default.
• W3216802214 hasConceptScore W3216802214C2780564577 @default.
• W3216802214 hasConceptScore W3216802214C47348012 @default.
• W3216802214 hasConceptScore W3216802214C50345908 @default.
• W3216802214 hasConceptScore W3216802214C71924100 @default.
• W3216802214 hasConceptScore W3216802214C74172505 @default.
• W3216802214 hasConceptScore W3216802214C98274493 @default.
• W3216802214 hasIssue "5" @default.
• W3216802214 hasLocation W32168022141 @default.
• W3216802214 hasLocation W32168022142 @default.
• W3216802214 hasOpenAccess W3216802214 @default.
• W3216802214 hasPrimaryLocation W32168022141 @default.
• W3216802214 hasRelatedWork W2079598877 @default.
• W3216802214 hasRelatedWork W2116633865 @default.
• W3216802214 hasRelatedWork W2296439405 @default.

• next